Zanzalintinib + Cemiplimab for Thyroid Cancer

This trial tests a combination of two treatments, zanzalintinib and cemiplimab (an immunotherapy drug), to determine if they can extend the life expectancy of people with an aggressive form of thyroid cancer. Participants will receive these treatments in cycles, aiming to improve survival by about four months. The trial seeks participants with advanced thyroid cancer that cannot be surgically removed or has spread to other parts of the body. Eligible individuals often have specific types of thyroid cancer that impact daily life, such as difficulty swallowing or breathing. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering a chance to contribute to significant advancements in thyroid cancer treatment.

The trial protocol does not specify if you need to stop all current medications, but certain medications are prohibited. You must stop taking any small molecule kinase inhibitors, cytotoxic or biologic therapies, and certain anticoagulants before starting the trial. It's best to discuss your current medications with the trial team to see if any adjustments are needed.

Research has shown that the combination of zanzalintinib and cemiplimab can be safe and manageable for patients. Other studies have demonstrated promising results for this combination in treating certain types of thyroid cancer. For instance, similar drug combinations have proven safe, with manageable side effects for some patients. Additionally, when combined with another drug, zanzalintinib has shown a high success rate in controlling the disease, indicating it is generally well-tolerated.

Researchers are excited about Zanzalintinib + Cemiplimab for thyroid cancer because this combination targets the cancer in a novel way. Unlike traditional treatments such as surgery or radioactive iodine, Zanzalintinib is a small molecule inhibitor, which means it can block specific proteins that encourage cancer growth. Cemiplimab is an immune checkpoint inhibitor, which helps the body's immune system recognize and attack cancer cells more effectively. Together, these treatments could offer a more targeted approach, potentially leading to better outcomes for patients.

Research shows that combining zanzalintinib and cemiplimab may help treat thyroid cancer. Studies have found that patients with certain thyroid conditions live longer without their cancer worsening when treated with cemiplimab. Zanzalintinib has also been tested with similar drugs, showing improved survival rates in cancer patients. This trial examines the combination of zanzalintinib and cemiplimab in anaplastic thyroid cancer, as it might enhance the immune system's ability to fight the cancer. These findings suggest that this treatment could extend the lives of thyroid cancer patients.¹²³⁴⁶